Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 7 days · First seen 15 days ago · Last updated 8 days ago

GC Biopharma influenza vaccine development

Overview

GC Biopharma has expanded its influenza vaccine development through international partnerships and domestic clinical advancements.

In late August 2026, GC Biopharma entered a strategic partnership with French biotechnology firm Osivax to co-develop a next-generation influenza vaccine. This collaboration aims to merge GC Biopharma’s ‘GC Flu’ with Osivax’s ‘OVX836’ candidate using a nanoparticle platform to trigger both T-cell and B-cell immune responses. Under the agreement, GC Biopharma holds exclusive rights for commercialization in South Korea, while Osivax leads global development.

By early September 2026, GC Biopharma received approval from the Ministry of Food and Drug Safety to begin Phase 2/3 clinical trials for ‘GC3114B’, a high-immunogenicity vaccine candidate. These trials will focus on safety and efficacy in individuals aged 65 and older. To support this, the company has established a manufacturing strategy through a partnership with Korea Vaccine to utilize pre-filled syringe production facilities.

Entities

GC Biopharma · GC Flu · Korea Disease Control and Prevention Agency · OVX836 · Heo Eun-cheol

Timeline

8 days ago

[BUSINESS] 2 sources
GC Biopharma receives approval for elderly influenza vaccine trials
GC Biopharma received regulatory approval for Phase 2/3 clinical trials of GC3114B, a high-immunogenicity influenza vaccine designed to provide stronger protection for adults aged 65 and older.
15 days ago

[BUSINESS] 4 sources
GC Biopharma and Osivax partner to develop next-generation flu vaccine
GC Biopharma and France's Osivax are partnering to develop a next-generation dual-mechanism influenza vaccine targeting broader protection against viral mutations.

Sources

biz.heraldcorp.com · bosa.co.kr · kormedi.com · techholic.co.kr